Overview

Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity

Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
0
Participant gender:
All
Summary
To explore the efficacy of triflusal in the attenuation of insulin resistance in human obesity. Triflusal is a salicylate compound approved in several countries as antithrombotic agent (antiplatelet). The hypothesis is to explore if there is a reduction of obesity-induced insulin resistance by triflusal.
Phase:
Phase 2
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
J. Uriach and Company
Treatments:
Insulin
Insulin, Globin Zinc
Salicylates
Triflusal
Criteria
Inclusion Criteria:

- Ages 35 to 60 years old